Obtenga las últimas noticias sobre las acciones de Protalix BioTherapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de PLX

Últimas noticias sobre

Protalix BioTherapeutics

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics Inc

Plexus Corp

Piolax Inc

Pluxee NV

PLx Pharma Inc

PLx Pharma Winddown Corp

Press Releases

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Earnings

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Biotech

Events

Protalix BioTherapeutics to Present at Investor Summit Virtual

Health Care

Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU

Adicet Bio

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

C4 Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Elicio Therapeutics

Fate Therapeutics

Genfit

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Nkarta

Nuvectis Pharma

Palisade Bio

Pyxis Oncology

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Vor Biopharma

Zura Bio Limited - Class A Ordinary shares

Comments

Protalix BioTherapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL